Data from multiple sources - Curated by Toby Galbraith - Last updated 06 June 2017

Inflammatory condition of skin

This section encompasses a wide range of skin conditions, comprising a number of separate aetiologies. They fall into this category due to their common inflammatory pathology,

...


Read more on Inflammatory condition of skin

 

 

Latest news articles

Added 12 days ago Drug news

FDA Advisory Committee recommends tofacitinib for the treatment of adult patients with active psoriatic arthritis. - Pfizer

Pfizer Inc. announced that FDA Arthritis Advisory Committee (AAC) voted 10 to 1 to recommend approval of the proposed dose...

Added 29 days ago Drug news

EU Commission approves Kyntheum (brodalumab) of moderate-to-severe plaque psoriasis.- Leo Pharma

AstraZeneca and MedImmune, announced that its partner Leo Pharma has been granted full marketing authorisation in all 28 EU member...

Added 1 month ago Drug news

FDA approves Tremfya (guselkumab) to treat plaque psoriasis.- Janssen Biotech.

Janssen Biotech, Inc. announced that the FDA has approved Tremfya (guselkumab) for the treatment of adults living with moderate to...

Search all news articles for Inflammatory condition of skin
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress 2015

Visit IL-17A in Psoriasis


Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more

Visit Psoriasis


Guidelines

Psoriasis overview NICE Pathways

This document contains a single pathway diagram and uses numbering to link the boxes to the associated recommendations.

Added 6 months ago

Canadian Guidelines for the Management of Plaque Psoriasis 2009

Since the publication of the 2009 Canadian Guidelines for the Management of Plaque Psoriasis, significant advances have been made in determining the role of T cells in inflammatory and autoimmune diseases. 

Added 6 months ago

Adalimumab for treating moderate to severe hidradenitis suppurativa

Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

Added 6 months ago

Search all guidelines for Inflammatory condition of skin
 

Journal articles

Brodalumab for the treatment of psoriasis.

Introduction: Psoriasis is a complex disease in which the alteration of the IL-23/Th17 axis appears to be crucial for its pathogenic mechanisms, and anti-IL17 agents are rapidly becoming important therapeutic tools.

Added 5 days ago

Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.

Background: Psoriasis is an inflammatory skin disease that affects 2–3% of the worldwide population. The interleukin-17 cytokine family has been proven to play a central role in the pathogenesis of psoriasis.

Added 5 days ago

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.

Brodalumab is a novel fully human immunoglobulin G2 monoclonal antibody that antagonizes the interleukin (IL)-17 pathway by binding with high affinity to human IL-17RA.

Added 5 days ago

Search all journal articles for Inflammatory condition of skin
 

Clinical trials

A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis

This is a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA)...

Added 6 months ago

Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects (HS rPMS)

The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.

Added 6 months ago

Search all clinical trials for Inflammatory condition of skin
 

CME

Psoriasis: diagnosis and individualised therapy

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
15

Ask an expert: Psoriasis

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Psoriasis: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0
Search all CME for Inflammatory condition of skin